Labcorp Files 8-K on Material Agreement and Financial Obligation
Ticker: LH · Form: 8-K · Filed: Aug 23, 2024 · CIK: 920148
| Field | Detail |
|---|---|
| Company | Labcorp Holdings Inc. (LH) |
| Form Type | 8-K |
| Filed Date | Aug 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.10, $300 million, $300 m, $700 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Labcorp just signed a big deal and took on debt, details to come.
AI Summary
On August 23, 2024, LABCORP HOLDINGS INC. filed an 8-K report detailing the entry into a material definitive agreement and the creation of a direct financial obligation. The filing does not specify the other parties involved, the exact nature of the agreement, or the financial amounts associated with this obligation.
Why It Matters
This filing indicates a significant new agreement or debt for Labcorp, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and a direct financial obligation, suggesting potential financial commitments or changes that warrant attention.
Key Players & Entities
- LABCORP HOLDINGS INC. (company) — Registrant
- August 23, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by LABCORP HOLDINGS INC.?
The filing does not specify the nature of the material definitive agreement.
Who are the other parties involved in the material definitive agreement?
The filing does not disclose the names of the other parties involved in the agreement.
What is the specific financial obligation created by LABCORP HOLDINGS INC.?
The filing states the creation of a direct financial obligation but does not provide specific details or amounts.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 23, 2024.
Does this filing include financial statements or exhibits?
Yes, the filing indicates that financial statements and exhibits are included.
Filing Stats: 1,000 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2024-08-23 16:45:02
Key Financial Figures
- $0.10 — nge on which registered Common Stock , $0.10 par value LH New York Stock Exchange
- $300 million — subsidiaries, entered into a three-year $300 million accounts receivable securitization faci
- $300 m — defined below) to draw up to a total of $300 million, subject to the outstanding amoun
- $700 million — on to increase the facility limit up to $700 million subject to satisfaction of certain cond
Filing Documents
- lh-20240823.htm (8-K) — 31KB
- exhibit101receivablespurch.htm (EX-10.1) — 1308KB
- exhibit102saleagreement.htm (EX-10.2) — 393KB
- exhibit103performanceguara.htm (EX-10.3) — 79KB
- 0000920148-24-000103.txt ( ) — 2241KB
- lh-20240823.xsd (EX-101.SCH) — 2KB
- lh-20240823_lab.xml (EX-101.LAB) — 22KB
- lh-20240823_pre.xml (EX-101.PRE) — 12KB
- lh-20240823_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On August 23, 2024, Labcorp Holdings Inc. (the "Company") and certain of its subsidiaries, entered into a three-year $300 million accounts receivable securitization facility (the "Securitization Facility") with PNC Bank, National Association ("PNC"), as administrative agent. The Securitization Facility permits Labcorp Receivables (as defined below) to draw up to a total of $300 million, subject to the outstanding amount of the eligible receivables pool and other factors. The Securitization Facility contains an accordion to increase the facility limit up to $700 million subject to satisfaction of certain conditions. In connection with the Securitization Facility, on August 23, 2024, Laboratory Corporation of America Holdings ("LCAH") and Laboratory Corporation of America (the "Originators") sold and/or contributed all of their existing, and committed to continue to sell and/or contribute their future accounts receivable and certain related assets to Labcorp Receivables LLC, a special purpose vehicle and wholly-owned subsidiary of the Company and LCAH (the "Labcorp Receivables") pursuant to the terms of the Sale and Contribution Agreement, dated as of August 23, 2024 (the "Sale Agreement"), among the Originators, any additional originators from time to time party thereto, LCAH, as servicer, and Labcorp Receivables. Pursuant to the Receivables Purchase Agreement, dated as of August 23, 2024 (the "Receivables Purchase Agreement"), among Labcorp Receivables, the purchasers from time to time party thereto (the "Purchasers") and PNC Capital Markets LLC, Labcorp Receivables may sell and/or obtain financing for the accounts receivable assets and grants a security interest in all of its assets. LCAH will service the accounts receivables on behalf of Labcorp Receivables for a fee. In addition, pursuant to a Performance Guaranty, dated August 23, 2024 by the Company in favor of PNC, the Company has agreed to guarantee th
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Exhibit Name Exhibit 10.1 Receivables Purchase Agreement dated as of August 23, 2024 Exhibit 10.2 Sale and Contribution Agreement dated August 23, 2024 Exhibit 10.3 Performance Guaranty dated August 23, 2024 Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LABCORP HOLDINGS INC. Registrant By: /s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary August 23, 2024